Khaitan & Co acted as India counsel and advised Startek Inc. on cross-border merger of Startek Inc. with CCI Consulting FZCO and CCI Enterprises FZCO to create a scaled, PE-backed global customer experience (CX) platform. The transaction involved a complex multi-jurisdictional merger structure spanning the United States and UAE, with integration of multiple global subsidiaries.
Khaitan & Co advised Trimex Foods Pvt Ltd (“Trimex”) and its promoters and existing shareholders, in relation to primary issuance of securities by Trimex to the SG India Delta Holdings, LLC ("Investor"), and secondary purchase of securities by the Investor from the promoters and existing shareholders of Trimex.
Khaitan & Co is representing Amneal Pharmaceuticals, LLC (Amneal) as India counsels, alongside Simpson Thacher & Bartlett LLP in relation to its announced agreement to acquire 100% of Kashiv Biosciences LLC ("Kashiv"), a vertically integrated biopharmaceutical company incorporated in the United States of America, with 2 (two) subsidiaries in India (namely, Kashiv Biosciences Pvt Ltd and Kashiv Research Pvt Ltd), in a transaction with consideration that includes USD 375 million of cash and USD 375 mill
Khaitan and Co, alongside Linklaters LLP, advised Landis+Gyr AG on the divestiture of its EMEA business in India to AURELIUS Group (AURELIUS), a global alternative investment firm.
Khaitan & Co advised Everstone Capital on its partnership with the founding promoters of Apothecon Pharmaceuticals Pvt Ltd (India) and Navinta III Inc.
Khaitan & Co advised Just Climate LLP on its follow-on investment of INR 6.22 billion (c. USD 67.5 million) in Continuum Green Energy (following their previous investment of USD 150 million in September 2024).
Khaitan & Co advised Bosch Ltd, a leading supplier of technology and services, on the joint venture between Bosch Ltd, a leading supplier of technology and services, and Tata AutoComp Systems Ltd (TACO), automotive components conglomerate, to unlock growth opportunities in India’s e-mobility segment.
Khaitan & Co advised Temasek in its follow-on investment in CureFit Healthcare Pvt Ltd, which operates the health and fitness platform ‘Cult.fit’ ahead of its proposed IPO. With this investment, Temasek's shareholding in the company increases to ~11.88% (subject to certain other criteria).
Khaitan & Co advised RSB Transmissions on its proposed acquisition of approximately 76% in Setco Auto Systems Pvt Ltd (SASPL) from Setco Automotive Ltd (SAL) and India Resurgence Fund (India RF), along with a further subscription by RSB at closing to support repayment of SASPL’s existing debt. The transaction closing is subject to customary consents and approvals.
Khaitan & Co advised DWS Group GmbH & Co. KGaA (“DWS”) in relation to its proposed acquisition of 40% of Nippon Life India AIF Management Ltd (“NAIF”), currently a wholly owned subsidiary of Nippon Life India Asset Management Ltd (“NAMI”) for a consideration of approx. INR 733 crores by subscribing to equity shares to be issued by NAIF by way of preferential allotment (“Proposed Transaction”).
